Disitamab vedotin

• Description :

  Disitamab vedotin (RC-48) is a newly developed antibody-active molecule conjugate (ADC) targeting human epidermal growth factor receptor 2 (HER2), consisting of hertuzumab coupled to monomethyl auristatin E (MMAE) via a cleavable linker. Disitamab vedotin showed anti-tumor and anti-proliferative activities in gastric cancer cells with different HER-2 expression levels and inhibited the expression of HER-2 protein in gastric cancer cells.

• Stability :

  ≥ 2 years

• Purity :

  >98% (HPLC)

• Weight :

  Approximately 144.15 kDa

• Molecular Formula :

  ——

• Notes :

  Research use only, not for human use.

• Receptor :

  Antibody-Drug Conjugates (ADCs) | EGFR

• CAS Number :

  2136633-23-1